Publications in collaboration with researchers from Nanfang Hospital (1)

2016

  1. Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): An open-label, randomised, phase 3 trial

    The Lancet Oncology, Vol. 17, Núm. 3, pp. 357-366